MedTrace Logo

Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19

NCT04425863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.

Conditions

  • Severe Acute Respiratory Syndrome
  • Ventilation Pneumonitis

Interventions

DRUG

Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets

24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.

OTHER

Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets

36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator

OTHER

Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.

48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.

Sponsors & Collaborators

  • Eurnekian Public Hospital

    lead OTHER

Principal Investigators

  • Alfredo Secchi, M.D. · President Ethical Commitee, Hospital Eurnekian

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-08-30
Completion
2020-08-30

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425863 on ClinicalTrials.gov